ClinicalTrials.gg

Diarrhea clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 879 studies for Diarrhea across more than 10 countries. 78 are recruiting or about to start. 520 of them are mainly about Diarrhea (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Diarrhea, Infantile too: 899 studies, 82 open.

ClinicalTrials.gov finds 1,215 studies for Diarrhea. How that becomes 876 here

This page counts the studies the registry files under Diarrhea, and those it files under no condition that list Diarrheathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,215Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −20Filed under a narrower condition, counted on its own pageDiarrhea, Infantile 20
  3. −103List Diarrhea as a condition, but the registry did not file them under itMost often written as “Irritable Bowel Syndrome With Diarrhea” (16), “Antibiotic-associated Diarrhea” (9), and “Chronic Diarrhea” (8). The registry filed them under other conditions only, most often Irritable Bowel Syndrome (31) and Dysentery (13).
  4. −216Match it another way140 name it in the title, 38 in a keyword, and 38 by a synonym or other text the search reads.
  5. 876The count on this page175 of them list Diarrhea in their own words; the registry filed them under no condition.

Status

Completed
595
Status unknown
95
Terminated
63
Recruiting
45
Withdrawn
26
Not yet recruiting
26

Phase

Phase 2
177
Phase 3
149
Phase 4
94
Phase 1
76
Early Phase 1
13

Where

United States
249
China
50
Bangladesh
46
Canada
45
India
42
United Kingdom
33

Who develops what

Add Diarrhea to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 6 companies, 4 with this as their studies’ main aim; 0 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Bausch Health Companies, Eli Lilly and GlaxoSmithKline here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Meningococcal VaccinesRecent, limited
Evidence
  • NCT07320716 · GlaxoSmithKline · Phase 2 · live · comparator · “Menveo” · registered Dec 2025
  • NCT05073003 · GlaxoSmithKline · Phase 2 · comparator · “Menveo” · registered Sep 2021
—11 study
VancomycinEarlier only
Evidence
  • NCT04802837 · Summit Therapeutics · Phase 3 · comparator · “Vancomycin” · registered Mar 2021
  • NCT01598311 · Merck & Co., Inc · Phase 3 · comparator · “Vancomycin” · registered May 2012
  • NCT01597505 · Merck & Co., Inc · Phase 3 · comparator · “Vancomycin” · registered May 2012
  • NCT01085591 · Merck & Co., Inc · Phase 2 · comparator · “Vancomycin” · registered Mar 2010
  • NCT00468728 · Merck & Co., Inc · Phase 3 · comparator · “Vancomycin” · registered May 2007
Pfizer27% of its industry studiesUS: off-patent, 32 generics marketed00 studies
RifaximinEarlier only
Evidence
  • NCT02920242 · Novartis · Phase 3 · comparator · “Rifaximin (Xifaxan)” · registered Sep 2016
  • NCT02498418 · Teva Pharmaceutical Industries, Ltd. · Phase 3 · comparator · “Xifaxan®” · registered Jul 2015
Bausch Health Companies Inc.73% of its industry studiesUS: SALIX PHARMS (FDA 2004)00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules) · Shanghai United Cell Biotechnology Co., Ltd · Phase 4 main aimNCT07300462 A Post-marketing Observational Study of Oral Cholera Vaccine — primary endpoint: the incidence of infectious diarrhea in the vaccinated group and placebo group · 6,000 enrolled
  • 20 Apr 2027 est.Rifaximin · Bausch Health Companies Inc. · Phase 4 main aimNCT07285785 Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea — primary endpoint: Peak Plasma Concentration (Cmax) of Rifaximin · 54 enrolled
  • 31 Aug 2027 est.Huanghou Zhixie Diwan group · Lei Yunshang Group · Phase 2 main aimNCT07721012 Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) — primary endpoint: Effective rate of IBS-D (weekly response) · 120 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Diarrhea studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antiemetics 10 · 5-HT3 antagonists 10 · Corticosteroids 5

Coming up

33studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger. 19 (42%) take children under 18. 4 (9%) are for women only and 0 (0%) for men only; 15 (33%) take healthy volunteers.

Recruiting studies that take each age, of 45
AgeWomenMen
109 (20%)7 (16%)
1832 (71%)28 (62%)
3033 (73%)29 (64%)
4033 (73%)29 (64%)
5032 (71%)28 (62%)
6531 (69%)27 (60%)
7526 (58%)23 (51%)
8522 (49%)19 (42%)

Across all 879 studies, recruiting or not: 58% stop at 75 or younger and 50% at 65; 42% take children; 3% are for women only and 2% for men only; 34% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diarrhea studies take

Of 47 phase 2 interventional studies under Diarrhea, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 114 mo6–23 · 22 studies——
Phase 215 mo11–29 · 47 studies13 mo11–20 · 24 studies—
Phase 329 mo19–38 · 30 studies——
Phase 432 mo14–46 · 37 studies—37 mo14–48 · 32 studies
Interventional, no phase14 mo5–35 · 164 studies11 mo3–23 · 35 studies17 mo6–36 · 129 studies
Observational28 mo12–43 · 42 studies—28 mo12–47 · 34 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 879. Browse all 879 → or search them.